Atom and NSK Announce Strategic Partnership to Help Develop the Humanoid Robot Industry in Japan

Insider Brief

  • Atom and NSK signed a memorandum of understanding to jointly develop and test humanoid robot components and AI systems in Japan, with the goal of strengthening domestic production.
  • The companies will test NSK-developed actuators on Atom humanoid robots and use the results to improve performance and address mass-production requirements.
  • Atom and NSK will also use NSK manufacturing sites to collect real-world physical AI data intended to improve Atom’s models and develop robots for more advanced manufacturing tasks.

Atom and NSK have signed a memorandum of understanding to jointly develop and test components and AI systems in Japan to bolster domestic production of humanoid robots

The partnership will combine Atom’s robotics and AI technology with NSK’s precision-component development and mass-production capabilities, according to Atom. The companies said they intend to build a more integrated development and production system in Japan while also collecting real-world data needed to improve physical AI models. The two companies did not provide a timetable for commercial deployment or mass production of a completed humanoid robot.

Atom indicated that Japan currently has a limited number of companies attempting to build a large-scale domestic humanoid robotics industry, creating challenges around supply stability and manufacturing capacity.

“The integration of physical AI and hardware is essential for the implementation of humanoid robots, Atom president and CEO Shunsuke Aoki said in the announcement. “However, achieving a high-quality fusion of the two is extremely difficult, and successful examples are limited globally. NSK Ltd. is a world leader in precision components. By combining their outstanding hardware technology with our physical AI platform model development capabilities, we can realize the highest quality humanoid robots made in Japan.”

What Does the Atom and NSK Agreement Cover?

One part of the agreement will focus on actuators, the components that drive a robot’s joints and movement. NSK-developed actuators will be installed on Atom humanoid robots for testing, with data from those evaluations used to improve performance and address issues related to mass production.

The companies will also use NSK manufacturing sites to collect physical AI data with Atom humanoid robots. Atom said information gathered from production environments will be used to improve its physical AI platform model and develop robots capable of handling more advanced manufacturing tasks.

NSK’s representative executive officer, president and CEO Akihito Ichii said the company is working to support Japan’s robotics industry by supplying precision components and helping build a domestic humanoid sector capable of competing globally.

“Realizing a society where robots work alongside humans requires the integration of superior AI and robust hardware to support it,” Ichii said. “We will continue to pursue the reliability and durability required by the field, ensuring that our precision components support the movements of Atom’s humanoid robots.”

In June, Atom announced it had raised 3 billion yen, or nearly $19 million, in seed funding to develop AI-powered humanoid robots for manufacturing, logistics and transportation. The round was co-led by ANRI, Beyond Next Ventures and JAFCO Group, with the funding earmarked for hiring, development infrastructure, commercialization and work toward future mass production.

Image credit: Atom

Need Deeper Intelligence on the AI Market?

AI Insider's Market Intelligence platform tracks funding rounds, competitive landscapes, and technology trends across the global AI ecosystem in real time. Get the data and insights your organization needs to make informed decisions.

Related Articles

Impossible Metals Reports its Eureka II Recovers Itself From the Ocean, Fully Autonomously

Insider Brief Impossible Metals has reported its Eureka II subsea vehicle completed an autonomous offshore recovery demonstration, locating and reconnecting with its surface vessel without

gloved hands drawing vaccine from vial with syringe
Insilico Medicine Convenes an Open Consortium For Benchmark Quality in AI-Driven Drug Discovery

Insider Brief PRESS RELEASE — Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the launch of the Open

Japan’s AI Strategy: From Society 5.0 to Generative AI

A policy analysis from August 2026 Japan was arguing about the shape of its AI future before most countries had a strategy at all. In

Stay Updated with AI Insider

Get the latest AI funding news, market intelligence, and industry insights delivered to your inbox weekly.

$ 0 M

Seed round tracked

Gitar — Code Validation

Get the Weekly Briefing

Funding analysis, market intelligence, and industry trends delivered to your inbox every week.

Need bespoke intelligence?

Our team combines real-time data with decades of sector experience to guide your decisions.

Subscribe today for the latest news about the AI landscape